108 related articles for article (PubMed ID: 9716160)
1. Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium.
Glenn JR; Heptinstall S
Thromb Haemost; 1998 Aug; 80(2):321-5. PubMed ID: 9716160
[TBL] [Abstract][Full Text] [Related]
2. Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP.
Hardy E; Glenn J; Heptinstall S; Rubin PC; Horn EH
Thromb Haemost; 1995 Oct; 74(4):1132-7. PubMed ID: 8560425
[TBL] [Abstract][Full Text] [Related]
3. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
4. Octimibate inhibition of platelet aggregation: stimulation of adenylate cyclase through prostacyclin receptor activation.
Seiler S; Brassard CL; Arnold AJ; Meanwell NA; Fleming JS; Keely SL
J Pharmacol Exp Ther; 1990 Dec; 255(3):1021-6. PubMed ID: 2175792
[TBL] [Abstract][Full Text] [Related]
5. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
Packham MA; Mustard JF
Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
[TBL] [Abstract][Full Text] [Related]
6. Role of intracellular signaling events in ADP-induced platelet aggregation.
Daniel JL; Dangelmaier C; Jin J; Kim YB; Kunapuli SP
Thromb Haemost; 1999 Oct; 82(4):1322-6. PubMed ID: 10544922
[TBL] [Abstract][Full Text] [Related]
7. Mode of action of 2-(diethylamino)-7-ethoxychromone on human platelets.
Leoncini G; Maresca M; Colao C; Buzzi E; Mazzei M
Cell Biochem Funct; 1991 Apr; 9(2):79-85. PubMed ID: 1718622
[TBL] [Abstract][Full Text] [Related]
8. ADP-induced platelet aggregation and actin polymerization. Involvement of GpIIb/IIIa and the effect of Mg2+.
Heptinstall S; Glenn JR; Lösche W; Spangenberg P
Semin Thromb Hemost; 1995; 21(2):137-45. PubMed ID: 7660136
[TBL] [Abstract][Full Text] [Related]
9. Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.
Zahavi M; Zahavi J; Kakkar VV
Thromb Haemost; 1984 Oct; 52(2):205-9. PubMed ID: 6098048
[TBL] [Abstract][Full Text] [Related]
10. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.
Defreyn G; Gachet C; Savi P; Driot F; Cazenave JP; Maffrand JP
Thromb Haemost; 1991 Feb; 65(2):186-90. PubMed ID: 2053105
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of U46619 induced human platelet aggregation by aspirin.
Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS
Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
[TBL] [Abstract][Full Text] [Related]
12. Human platelet aggregation and cAMP system--cAMP level, adenyl cyclase, phosphodiesterase.
Wang TY; Hussey CV; Sasse EA; Fobian JE
Ann Clin Lab Sci; 1978; 8(5):403-12. PubMed ID: 213009
[TBL] [Abstract][Full Text] [Related]
13. Leukocyte count and leukocyte ecto-nucleotidase are major determinants of the effects of adenosine triphosphate and adenosine diphosphate on platelet aggregation in human blood.
Glenn JR; White AE; Johnson A; Fox SC; Behan MW; Dolan G; Heptinstall S
Platelets; 2005; 16(3-4):159-70. PubMed ID: 16011960
[TBL] [Abstract][Full Text] [Related]
14. Two different inhibitory effects of pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid on adenosine diphosphate-induced human platelet aggregation.
Windscheif U; Radziwon P; Breddin HK; Bäumert HG; Lambrecht G; Mutschler E
Arzneimittelforschung; 1995 Sep; 45(9):994-7. PubMed ID: 7488321
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
Fisch A; Michael-Hepp J; Meyer J; Darius H
Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway.
Dangelmaier C; Jin J; Smith JB; Kunapuli SP
Thromb Haemost; 2001 Feb; 85(2):341-8. PubMed ID: 11246558
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in adenosine triphosphate--induced platelet aggregation in whole blood.
Stafford NP; Pink AE; White AE; Glenn JR; Heptinstall S
Arterioscler Thromb Vasc Biol; 2003 Oct; 23(10):1928-33. PubMed ID: 12893689
[TBL] [Abstract][Full Text] [Related]
18. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
19. Influence of extracellular calcium on single platelet activation as measured by whole blood flow cytometry.
Hu H; Forslund M; Li N
Thromb Res; 2005; 116(3):241-7. PubMed ID: 15935833
[TBL] [Abstract][Full Text] [Related]
20. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
